Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission wer...Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission were divided into two combination group(control group, the combination of budesonide and terbutaline) and A. membranaceus group(treatment group, the combination of budesonide, terbutaline and A. membranaceus). The therapeutic results were compared between two groups after 3-month therapy.Porcine peripheral blood mononuclear cells(PBMCs) were isolated from venous blood by using density gradient centrifugation on percoll. The levels of Fox P3, EGF-β, IL-17 and IL-23 from PBMCs and serum Ig E were measured. The relative percentage of Treg/Th17 cells was determined using flow cytometry. The main components of A. membranaceus were calycosin-7-O-glucoside, isoquercitrin, ononin, calycosin, quercetin, genistein, kaempferol, isorhamnetin and formononetin, all of which may contribute to asthma therapy. Lung function was significantly improved in the treatment group when compared with a control group(P < 0.05). The efficacy in preventing the occurrence of childhood asthma was higher in the treatment group than the control group(P < 0.05).The levels of Ig E, IL-17 and IL-23 were reduced significantly in the treatment group when compared with the control group, while the levels of FoxP3 and TGF-β were increased in the treatment group when compared with the control group(P < 0.05). A. membranaceus increased the percentage of Treg cells and reduced the percentage of Th17 cells. A. membranaceus is potential natural product for improving the therapeutic efficacy of combination therapy of budesonide and terbutaline for the children with asthma remission by modulating the balance of Treg/Th17 cells.展开更多
目的观察过敏性紫癜(HSP)患儿肠黏膜屏障功能变化,探讨肠道菌群、L/M与Treg/Th17作用关系。方法采用细菌16S r DNA、液相色谱技术(HPLC)、流式细胞术(FCM)、酶联免疫法(ELISA)检测41例HSP急性期患儿、35例HSP临床缓解期患儿,及30例同期...目的观察过敏性紫癜(HSP)患儿肠黏膜屏障功能变化,探讨肠道菌群、L/M与Treg/Th17作用关系。方法采用细菌16S r DNA、液相色谱技术(HPLC)、流式细胞术(FCM)、酶联免疫法(ELISA)检测41例HSP急性期患儿、35例HSP临床缓解期患儿,及30例同期健康体检儿粪便中双歧杆菌、乳酸杆菌、大肠埃希菌和肠球菌的基因拷贝数,尿液中乳果糖(Lactulose)和甘露醇(Mannitol)浓度比值(L/M值),以及CD4+CD25+T细胞(Treg)和CD3+CD8-IL-17+(Th17)细胞百分比,及相应转化生长因子β1(TGF-β1)、白细胞介素-17(IL-17)水平。结果 HSP患儿急性期存在肠道菌群紊乱,表现在肠道中乳酸杆菌、双歧杆菌基因拷贝数降低,以乳酸杆菌减少为著,大肠埃希菌和肠球菌减少不明显;外周血单个核细胞(PBMC)中Th17百分数及血浆中IL-17水平增高,Treg细胞及TGF-β1水平降低,Treg/Th17失衡;尿液中L/M值增高。临床缓解期时患儿肠道双歧杆菌、乳酸杆菌基因拷贝数增加,以双歧杆菌上升为著,但肠道菌群结构仍未扶正;PBMC中Th17细胞百分数及血浆中IL-17水平降低,Treg细胞及TGF-β1水平逐渐升高,仍存在Treg/Th17失衡。肠道菌群中双歧杆菌/大肠埃希菌(B/E)比值与Treg/Th17呈正相关关系,与尿液中L/M值呈负相关。结论 HSP患儿急性期肠黏膜屏障功能受损,表现在机械、免疫屏障降低及肠道微生态失衡,肠道菌群所诱导的免疫耐受被打破,并贯穿HSP整个病理过程。展开更多
文摘Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission were divided into two combination group(control group, the combination of budesonide and terbutaline) and A. membranaceus group(treatment group, the combination of budesonide, terbutaline and A. membranaceus). The therapeutic results were compared between two groups after 3-month therapy.Porcine peripheral blood mononuclear cells(PBMCs) were isolated from venous blood by using density gradient centrifugation on percoll. The levels of Fox P3, EGF-β, IL-17 and IL-23 from PBMCs and serum Ig E were measured. The relative percentage of Treg/Th17 cells was determined using flow cytometry. The main components of A. membranaceus were calycosin-7-O-glucoside, isoquercitrin, ononin, calycosin, quercetin, genistein, kaempferol, isorhamnetin and formononetin, all of which may contribute to asthma therapy. Lung function was significantly improved in the treatment group when compared with a control group(P < 0.05). The efficacy in preventing the occurrence of childhood asthma was higher in the treatment group than the control group(P < 0.05).The levels of Ig E, IL-17 and IL-23 were reduced significantly in the treatment group when compared with the control group, while the levels of FoxP3 and TGF-β were increased in the treatment group when compared with the control group(P < 0.05). A. membranaceus increased the percentage of Treg cells and reduced the percentage of Th17 cells. A. membranaceus is potential natural product for improving the therapeutic efficacy of combination therapy of budesonide and terbutaline for the children with asthma remission by modulating the balance of Treg/Th17 cells.
文摘目的观察过敏性紫癜(HSP)患儿肠黏膜屏障功能变化,探讨肠道菌群、L/M与Treg/Th17作用关系。方法采用细菌16S r DNA、液相色谱技术(HPLC)、流式细胞术(FCM)、酶联免疫法(ELISA)检测41例HSP急性期患儿、35例HSP临床缓解期患儿,及30例同期健康体检儿粪便中双歧杆菌、乳酸杆菌、大肠埃希菌和肠球菌的基因拷贝数,尿液中乳果糖(Lactulose)和甘露醇(Mannitol)浓度比值(L/M值),以及CD4+CD25+T细胞(Treg)和CD3+CD8-IL-17+(Th17)细胞百分比,及相应转化生长因子β1(TGF-β1)、白细胞介素-17(IL-17)水平。结果 HSP患儿急性期存在肠道菌群紊乱,表现在肠道中乳酸杆菌、双歧杆菌基因拷贝数降低,以乳酸杆菌减少为著,大肠埃希菌和肠球菌减少不明显;外周血单个核细胞(PBMC)中Th17百分数及血浆中IL-17水平增高,Treg细胞及TGF-β1水平降低,Treg/Th17失衡;尿液中L/M值增高。临床缓解期时患儿肠道双歧杆菌、乳酸杆菌基因拷贝数增加,以双歧杆菌上升为著,但肠道菌群结构仍未扶正;PBMC中Th17细胞百分数及血浆中IL-17水平降低,Treg细胞及TGF-β1水平逐渐升高,仍存在Treg/Th17失衡。肠道菌群中双歧杆菌/大肠埃希菌(B/E)比值与Treg/Th17呈正相关关系,与尿液中L/M值呈负相关。结论 HSP患儿急性期肠黏膜屏障功能受损,表现在机械、免疫屏障降低及肠道微生态失衡,肠道菌群所诱导的免疫耐受被打破,并贯穿HSP整个病理过程。
